Jefo, a world leader in high-performance non-medicated nutritional solutions for animals, attended the 2023 International Production and Processing Expo (IPPE) held at Georgia World Congress Center in Atlanta, As a long time exhibitor, the Canadian company took some of its top executive members to the United States trade show in animal production. Despite his very busy schedule, Dr. Jean Fontaine, president and founder of the Jefo Group, ensured his presence along with directors, technical specialists and sales representatives from USA, Canada, Mexico, Brazil, Colombia and Costa Rica.
“We are always listening to the market needs. This kind of show, where we have a booth to welcome customers and industry experts, is ideal to establish contacts, but also to strengthen our existing relationships. I am very excited to attend the 2023 IPPE.”
The group celebrated its 40 years of activity in 2022 and will inaugurate the opening of its new microencapsulation production plant in the coming months. By investing 42.5 million Canadian dollars in this plant, Jefo will increase its current production up by 400% to meet the growing demand for domestic and international markets. The plant construction should be achieved in 2023 to start the production. “More than ever, the world understands the importance of sanitary issues to improve animal health and, consequently, human health," says Dr. Fontaine.
"Since our foundation, we have focused on solutions aimed to reduce antibiotic resistance by offering nutritional alternatives to livestock producers. We know that consumers pay a lot more attention to what they put on their plates, and we have ambitious goals to meet this growing demand. We expect to double our sales of specialty products in the next three years. Our Precision Intestinal Nutrition concept is a revolutionary approach focused on microbiota and gut harmony, and we are conducting many promising trials on these matters. We surround ourselves with world-class researchers to put our ideas to test and design the next era of precision nutrition.”
The new state-of-the-art 180,000 square feet microencapsulation plant will feature two production lines in the first phase with a potential expansion to six lines in the near future. The current plant will remain in operation, therefore maximizing production stability and security. “Fighting antibiotic resistance is essential to meet our vision of having a healthier circle of life on a more sustainable planet. Regulations on the quality of animal protein are changing in our favour and this new plant will allow us to offer our solutions to a greater number of producers. We are present in more than 80 countries, but we continue to develop innovative solutions and new markets,” confirms Fontaine.
“Our international team continues to grow, and our customer-oriented approach is major competitive advantages. We developed our presence on field with a strong team of experts present in different countries. Our partners know they can rely on our Applied Scientific Curiosity and our practical knowledge to find the best solutions to improve animal health and maximize their profits,” affirms Miguel Barrios, business development manager Monogastric USA.
